TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Nov. 6, 2026, MedpageToday roundup highlighted cautions about a small breast cancer risk increase associated with certain menopause hormone therapies, an estimated 2% Medicare physician payment cut for oncology care in 2027, and research questioning routine imaging after double mastectomy for ductal carcinoma in situ. The items describe separate developments; the supplied report does not establish a link among them.
A Nov. 6 cancer news roundup highlighted three developments affecting patients and oncology practice: doctors’ warning about a small increase in breast cancer risk associated with certain menopause hormone therapies, an estimated 2% Medicare payment cut for oncologists in 2027, and a report that routine breast imaging may not benefit women treated for ductal carcinoma in situ (DCIS) with double mastectomy. The items address different questions, and the available report does not connect them.
The roundup, published by MedpageToday, summarized coverage from several outlets and organizations. It said doctors warned against overlooking a small increase in breast cancer risk associated with certain hormonal therapies used to treat menopause symptoms. It also noted that the U.S. Food and Drug Administration had removed boxed warnings about breast cancer, cardiovascular disease and dementia from the labels of three estrogen patches, according to The Guardian. The supplied material does not identify the specific therapies behind the risk warning or provide the evidence and labeling rationale in detail.
On payment policy, the American Society of Clinical Oncology (ASCO) said oncologists treating Medicare patients face a roughly 2% pay cut under the 2027 Physician Fee Schedule from the Centers for Medicare & Medicaid Services. The roundup gives ASCO’s estimate but does not include the underlying fee schedule provisions, the method used to calculate the reduction, or details about possible exceptions. ASCO said it was monitoring the potential effect on cancer care delivery.
A third item, attributed to UCLA Health, said women who had a double mastectomy for DCIS may not benefit from routine mammograms or other breast imaging. The summary does not provide study design, patient numbers, follow-up duration or a specific clinical recommendation. Its wording is cautious: it says imaging may not help, rather than establishing that all patients can safely forgo follow-up imaging.
Implications for Patients and Clinics
Together, the three items touch decisions made by patients and clinicians: how to weigh symptom relief against possible risks from menopause hormone treatment, how to plan Medicare-funded oncology services amid a projected payment reduction, and what follow-up care may be appropriate after surgery for DCIS. Their relevance does not mean they share a single cause or policy response.
For patients, the hormone therapy report reinforces the need for individualized discussions rather than treating risk as identical across all medicines or patients. For oncology practices, a payment reduction could affect the financial conditions under which Medicare care is delivered, though the supplied report does not quantify any likely effect on appointments, staffing or treatment availability. The imaging item could inform follow-up conversations, but the summarized evidence is too limited to support changing an individual’s care plan on its own.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Therabody ThermBack LED 4-in-1 Heated Lower Back Relief Wrap
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
As an affiliate, we earn on qualifying purchases.
Three Separate Cancer Developments
The source is a brief collection of cancer-related news, not a single study or unified policy announcement. It combines reports from news organizations with statements from professional groups and a short description of research or clinical findings. That distinction matters: the hormone therapy warning, CMS payment projection and post-mastectomy imaging question have different evidence bases and responsible decision-makers.
In the same roundup, MedpageToday reported that the FDA had removed boxed warnings from labels of three estrogen patches. A boxed warning is a prominent label warning, but its removal does not by itself establish that a medicine has no risks. The roundup also described ASCO’s response to the anticipated 2027 payment schedule and cited UCLA Health on imaging after double mastectomy for DCIS. It offered no dates for the underlying FDA action or imaging research beyond the roundup’s publication date.
“Doctors are warning not to overlook the small increase in breast cancer risk associated with certain hormonal therapies for treating menopause symptoms.”
— Doctors, as summarized by MedpageToday
Evidence and Individual Risk Questions
The roundup does not provide enough detail to determine which hormone regimens carry the reported risk, how large the increase is in absolute terms, or how patients’ age, medical history and treatment duration affect it. It also does not explain the evidence or regulatory reasoning behind the FDA’s label changes. The removal of warnings and the separate caution about risk should not be read as contradictory without those details.
For the Medicare payment issue, the source does not show the final policy language or how the estimated reduction would apply across different oncology services and practices. For post-mastectomy imaging, it does not identify the study, describe recurrence outcomes, or specify which patients and circumstances were assessed. Whether follow-up imaging is appropriate for a particular person remains a clinical decision based on their history and care team’s advice.
Policy and Care Guidance Ahead
ASCO said it was monitoring the possible impact of the 2027 Medicare fee schedule on cancer care delivery. The supplied report does not state whether the association plans a formal analysis, advocacy effort or further public update, nor does it give a later milestone for the schedule.
Patients considering menopause hormone therapy should discuss the benefits and risks of their specific treatment with a qualified clinician; the roundup does not announce a new clinical guideline. People who have had a double mastectomy for DCIS should ask their care team what surveillance is appropriate for their individual case rather than infer that all imaging is unnecessary. Further details from the underlying research and clinical guidance would be needed to clarify how broadly the imaging finding applies.
Key Questions
Does the report say all menopause hormone therapy raises breast cancer risk?
No. It refers to a small increase associated with certain hormonal therapies and does not identify all treatments or quantify each patient’s risk.
What does the reported 2% oncology pay cut refer to?
ASCO said oncologists treating Medicare patients face a roughly 2% reduction under the 2027 Physician Fee Schedule. The roundup does not provide the calculation or detail how it applies to every service.
Can patients stop mammograms after a double mastectomy for DCIS?
The source says routine mammograms or other imaging may not benefit some women after double mastectomy for DCIS. It does not provide a universal recommendation; patients should ask their care team about follow-up for their circumstances.
Did the FDA’s removal of boxed warnings mean estrogen patches have no risks?
No such conclusion is supported by the roundup. It reports that warnings about breast cancer, cardiovascular disease and dementia were removed from labels of three estrogen patches, but provides no detailed rationale and does not say the patches are risk-free.
Source: medpagetoday.com
